Cargando…
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Drugs with prolonged, on-target residence time often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking. Here, we demonstrate progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversibl...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472506/ https://www.ncbi.nlm.nih.gov/pubmed/26006010 http://dx.doi.org/10.1038/nchembio.1817 |
_version_ | 1782377058272280576 |
---|---|
author | Bradshaw, J. Michael McFarland, Jesse M. Paavilainen, Ville O. Bisconte, Angelina Tam, Danny Phan, Vernon T. Romanov, Sergei Finkle, David Shu, Jin Patel, Vaishali Ton, Tony Li, Xiaoyan Loughhead, David G. Nunn, Philip A. Karr, Dane E. Gerritsen, Mary E. Funk, Jens Oliver Owens, Timothy D. Verner, Erik Brameld, Ken A. Hill, Ronald J. Goldstein, David M. Taunton, Jack |
author_facet | Bradshaw, J. Michael McFarland, Jesse M. Paavilainen, Ville O. Bisconte, Angelina Tam, Danny Phan, Vernon T. Romanov, Sergei Finkle, David Shu, Jin Patel, Vaishali Ton, Tony Li, Xiaoyan Loughhead, David G. Nunn, Philip A. Karr, Dane E. Gerritsen, Mary E. Funk, Jens Oliver Owens, Timothy D. Verner, Erik Brameld, Ken A. Hill, Ronald J. Goldstein, David M. Taunton, Jack |
author_sort | Bradshaw, J. Michael |
collection | PubMed |
description | Drugs with prolonged, on-target residence time often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking. Here, we demonstrate progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors. Utilizing an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, we identified potent and selective BTK inhibitors that demonstrate biochemical residence times spanning from minutes to 7 days. An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK more than 18 hours after clearance from the circulation. The inverted cyanoacrylamide strategy was further utilized to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating generalizability of the approach. Targeting noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates “residence time by design”, the ability to modulate and improve the duration of target engagement in vivo. |
format | Online Article Text |
id | pubmed-4472506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
record_format | MEDLINE/PubMed |
spelling | pubmed-44725062016-01-01 Prolonged and tunable residence time using reversible covalent kinase inhibitors Bradshaw, J. Michael McFarland, Jesse M. Paavilainen, Ville O. Bisconte, Angelina Tam, Danny Phan, Vernon T. Romanov, Sergei Finkle, David Shu, Jin Patel, Vaishali Ton, Tony Li, Xiaoyan Loughhead, David G. Nunn, Philip A. Karr, Dane E. Gerritsen, Mary E. Funk, Jens Oliver Owens, Timothy D. Verner, Erik Brameld, Ken A. Hill, Ronald J. Goldstein, David M. Taunton, Jack Nat Chem Biol Article Drugs with prolonged, on-target residence time often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking. Here, we demonstrate progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors. Utilizing an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, we identified potent and selective BTK inhibitors that demonstrate biochemical residence times spanning from minutes to 7 days. An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK more than 18 hours after clearance from the circulation. The inverted cyanoacrylamide strategy was further utilized to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating generalizability of the approach. Targeting noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates “residence time by design”, the ability to modulate and improve the duration of target engagement in vivo. 2015-05-25 2015-07 /pmc/articles/PMC4472506/ /pubmed/26006010 http://dx.doi.org/10.1038/nchembio.1817 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Bradshaw, J. Michael McFarland, Jesse M. Paavilainen, Ville O. Bisconte, Angelina Tam, Danny Phan, Vernon T. Romanov, Sergei Finkle, David Shu, Jin Patel, Vaishali Ton, Tony Li, Xiaoyan Loughhead, David G. Nunn, Philip A. Karr, Dane E. Gerritsen, Mary E. Funk, Jens Oliver Owens, Timothy D. Verner, Erik Brameld, Ken A. Hill, Ronald J. Goldstein, David M. Taunton, Jack Prolonged and tunable residence time using reversible covalent kinase inhibitors |
title | Prolonged and tunable residence time using reversible covalent kinase inhibitors |
title_full | Prolonged and tunable residence time using reversible covalent kinase inhibitors |
title_fullStr | Prolonged and tunable residence time using reversible covalent kinase inhibitors |
title_full_unstemmed | Prolonged and tunable residence time using reversible covalent kinase inhibitors |
title_short | Prolonged and tunable residence time using reversible covalent kinase inhibitors |
title_sort | prolonged and tunable residence time using reversible covalent kinase inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472506/ https://www.ncbi.nlm.nih.gov/pubmed/26006010 http://dx.doi.org/10.1038/nchembio.1817 |
work_keys_str_mv | AT bradshawjmichael prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT mcfarlandjessem prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT paavilainenvilleo prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT bisconteangelina prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT tamdanny prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT phanvernont prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT romanovsergei prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT finkledavid prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT shujin prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT patelvaishali prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT tontony prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT lixiaoyan prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT loughheaddavidg prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT nunnphilipa prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT karrdanee prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT gerritsenmarye prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT funkjensoliver prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT owenstimothyd prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT vernererik prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT brameldkena prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT hillronaldj prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT goldsteindavidm prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors AT tauntonjack prolongedandtunableresidencetimeusingreversiblecovalentkinaseinhibitors |